Loading…
Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors
Variant liver oestrogen receptor transcripts in hepatocellular carcinoma are associated with aggressive clinical course and unresponsiveness to tamoxifen. To evaluate the impact on survival and on tumour growth of megestrol (progestin drug acting at post-receptorial level) we enrolled 45 patients wi...
Saved in:
| Published in: | British journal of cancer 2001-04, Vol.84 (7), p.881-885 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c484t-23661d7ee429e6b42304a9ad9a97d347780b8f3e24117f703750cf2e02c6e9783 |
|---|---|
| cites | |
| container_end_page | 885 |
| container_issue | 7 |
| container_start_page | 881 |
| container_title | British journal of cancer |
| container_volume | 84 |
| creator | Villa, E Ferretti, I Grottola, A Buttafoco, P Buono, M Grazia Del Giannini, F Manno, M Bertani, H Dugani, A Manenti, F |
| description | Variant liver oestrogen receptor transcripts in hepatocellular carcinoma are associated with aggressive clinical course and unresponsiveness to tamoxifen. To evaluate the impact on survival and on tumour growth of megestrol (progestin drug acting at post-receptorial level) we enrolled 45 patients with HCC characterized by variant liver oestrogen receptors in a prospective, randomized study with megestrol vs. placebo. Presence of variant oestrogen receptors was determined by RT/PCR. 24 patients were randomized to no treatment and 21 to therapy with megestrol 160 mg day
–1
. Results were analysed by Kaplan-Meier and Cox methods. Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (
P
= 0.0090). Tumour growth at one year was significantly slowed down in megestrol-treated patients (
P
= 0.0212). Bilirubin levels, presence of portal thrombosis, HBV aetiology and treatment were identified at univariate analysis as factors significantly associated with survival; at multivariate analysis, only megestrol therapy (
P
= 0.0003), presence of HBV infection (
P
= 0.0009) and presence of portal vein thrombosis (
P
= 0.0051) were factors independently related with survival. (1) Megestrol slows down the aggressive tumour growth of patients with hepatocellular carcinoma characterized by variant estrogen receptors and (2) is also able to favourably influence the course of disease, more than doubling median survival. © 2001 Cancer Research Campaign |
| doi_str_mv | 10.1054/bjoc.2000.1534 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1008677351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-23661d7ee429e6b42304a9ad9a97d347780b8f3e24117f703750cf2e02c6e9783</originalsourceid><addsrcrecordid>eNp1kUFr3DAQhUVpabZJrz0WUXL1RpZlS74USkiaQqCX5izG8njtRbbckTdl--uj7S5NcygIhtF8ejOax9iHXKxzUaqrZhvcWgqR0rJQr9gqBZnlRurXbJWudSZqKc7Yuxi3Ka2F0W_ZWZ5LU6mqXLF4F2gME3i-9Egw7_mvYen5iBuMCwXPhymdMKda45H3OMMSHHq_80DcAblUHYG7HgjcgjT8xpY3e_4INMC08PBHZ4MTJ3Q4L4HiBXvTgY_4_hTP2cPtzY_ru-z--9dv11_uM6eMWjJZVFXeakQla6waJQuhoIa2hlq3hdLaiMZ0BUqV57rTotClcJ1EIV2FtTbFOft81J13zYitw2kh8HamYQTa2wCDfVmZht5uwqNNnQujyiTw6SRA4ecufcRuw47SsmJC0jZNZVSC1kfIUYiRsPvbIBf24JE9eGQPHtmDR-nBx3_HesZPpiTg8gRAdOA7gskN8QWn6zphV0cspsq0QXqe7j-dnwB5lay-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230008684</pqid></control><display><type>article</type><title>Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors</title><source>PubMed (Medline)</source><creator>Villa, E ; Ferretti, I ; Grottola, A ; Buttafoco, P ; Buono, M Grazia Del ; Giannini, F ; Manno, M ; Bertani, H ; Dugani, A ; Manenti, F</creator><creatorcontrib>Villa, E ; Ferretti, I ; Grottola, A ; Buttafoco, P ; Buono, M Grazia Del ; Giannini, F ; Manno, M ; Bertani, H ; Dugani, A ; Manenti, F</creatorcontrib><description>Variant liver oestrogen receptor transcripts in hepatocellular carcinoma are associated with aggressive clinical course and unresponsiveness to tamoxifen. To evaluate the impact on survival and on tumour growth of megestrol (progestin drug acting at post-receptorial level) we enrolled 45 patients with HCC characterized by variant liver oestrogen receptors in a prospective, randomized study with megestrol vs. placebo. Presence of variant oestrogen receptors was determined by RT/PCR. 24 patients were randomized to no treatment and 21 to therapy with megestrol 160 mg day
–1
. Results were analysed by Kaplan-Meier and Cox methods. Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (
P
= 0.0090). Tumour growth at one year was significantly slowed down in megestrol-treated patients (
P
= 0.0212). Bilirubin levels, presence of portal thrombosis, HBV aetiology and treatment were identified at univariate analysis as factors significantly associated with survival; at multivariate analysis, only megestrol therapy (
P
= 0.0003), presence of HBV infection (
P
= 0.0009) and presence of portal vein thrombosis (
P
= 0.0051) were factors independently related with survival. (1) Megestrol slows down the aggressive tumour growth of patients with hepatocellular carcinoma characterized by variant estrogen receptors and (2) is also able to favourably influence the course of disease, more than doubling median survival. © 2001 Cancer Research Campaign</description><identifier>ISSN: 0007-0920</identifier><identifier>ISSN: 1532-1827</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1054/bjoc.2000.1534</identifier><identifier>PMID: 11286465</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Alternative Splicing ; Antineoplastic agents ; Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - metabolism ; Carcinoma, Hepatocellular - pathology ; Cell Division - drug effects ; Chemotherapy ; Drug Resistance ; Epidemiology ; Female ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - metabolism ; Liver Neoplasms - pathology ; Male ; Medical sciences ; Megestrol - adverse effects ; Megestrol - therapeutic use ; Middle Aged ; Molecular Medicine ; Oncology ; Pharmacology. Drug treatments ; Prospective Studies ; Receptors, Estrogen - genetics ; Receptors, Estrogen - metabolism ; Regular ; regular-article ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Survival Rate</subject><ispartof>British journal of cancer, 2001-04, Vol.84 (7), p.881-885</ispartof><rights>The Author(s) 2001</rights><rights>2001 INIST-CNRS</rights><rights>Copyright 2001 Cancer Research Campaign.</rights><rights>Copyright Nature Publishing Group Apr 2001</rights><rights>Copyright © 2001 Cancer Research Campaign 2001 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-23661d7ee429e6b42304a9ad9a97d347780b8f3e24117f703750cf2e02c6e9783</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363845/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363845/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1128799$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11286465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Villa, E</creatorcontrib><creatorcontrib>Ferretti, I</creatorcontrib><creatorcontrib>Grottola, A</creatorcontrib><creatorcontrib>Buttafoco, P</creatorcontrib><creatorcontrib>Buono, M Grazia Del</creatorcontrib><creatorcontrib>Giannini, F</creatorcontrib><creatorcontrib>Manno, M</creatorcontrib><creatorcontrib>Bertani, H</creatorcontrib><creatorcontrib>Dugani, A</creatorcontrib><creatorcontrib>Manenti, F</creatorcontrib><title>Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Variant liver oestrogen receptor transcripts in hepatocellular carcinoma are associated with aggressive clinical course and unresponsiveness to tamoxifen. To evaluate the impact on survival and on tumour growth of megestrol (progestin drug acting at post-receptorial level) we enrolled 45 patients with HCC characterized by variant liver oestrogen receptors in a prospective, randomized study with megestrol vs. placebo. Presence of variant oestrogen receptors was determined by RT/PCR. 24 patients were randomized to no treatment and 21 to therapy with megestrol 160 mg day
–1
. Results were analysed by Kaplan-Meier and Cox methods. Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (
P
= 0.0090). Tumour growth at one year was significantly slowed down in megestrol-treated patients (
P
= 0.0212). Bilirubin levels, presence of portal thrombosis, HBV aetiology and treatment were identified at univariate analysis as factors significantly associated with survival; at multivariate analysis, only megestrol therapy (
P
= 0.0003), presence of HBV infection (
P
= 0.0009) and presence of portal vein thrombosis (
P
= 0.0051) were factors independently related with survival. (1) Megestrol slows down the aggressive tumour growth of patients with hepatocellular carcinoma characterized by variant estrogen receptors and (2) is also able to favourably influence the course of disease, more than doubling median survival. © 2001 Cancer Research Campaign</description><subject>Alternative Splicing</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cell Division - drug effects</subject><subject>Chemotherapy</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Megestrol - adverse effects</subject><subject>Megestrol - therapeutic use</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Receptors, Estrogen - genetics</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Regular</subject><subject>regular-article</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Survival Rate</subject><issn>0007-0920</issn><issn>1532-1827</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNp1kUFr3DAQhUVpabZJrz0WUXL1RpZlS74USkiaQqCX5izG8njtRbbckTdl--uj7S5NcygIhtF8ejOax9iHXKxzUaqrZhvcWgqR0rJQr9gqBZnlRurXbJWudSZqKc7Yuxi3Ka2F0W_ZWZ5LU6mqXLF4F2gME3i-9Egw7_mvYen5iBuMCwXPhymdMKda45H3OMMSHHq_80DcAblUHYG7HgjcgjT8xpY3e_4INMC08PBHZ4MTJ3Q4L4HiBXvTgY_4_hTP2cPtzY_ru-z--9dv11_uM6eMWjJZVFXeakQla6waJQuhoIa2hlq3hdLaiMZ0BUqV57rTotClcJ1EIV2FtTbFOft81J13zYitw2kh8HamYQTa2wCDfVmZht5uwqNNnQujyiTw6SRA4ecufcRuw47SsmJC0jZNZVSC1kfIUYiRsPvbIBf24JE9eGQPHtmDR-nBx3_HesZPpiTg8gRAdOA7gskN8QWn6zphV0cspsq0QXqe7j-dnwB5lay-</recordid><startdate>20010406</startdate><enddate>20010406</enddate><creator>Villa, E</creator><creator>Ferretti, I</creator><creator>Grottola, A</creator><creator>Buttafoco, P</creator><creator>Buono, M Grazia Del</creator><creator>Giannini, F</creator><creator>Manno, M</creator><creator>Bertani, H</creator><creator>Dugani, A</creator><creator>Manenti, F</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20010406</creationdate><title>Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors</title><author>Villa, E ; Ferretti, I ; Grottola, A ; Buttafoco, P ; Buono, M Grazia Del ; Giannini, F ; Manno, M ; Bertani, H ; Dugani, A ; Manenti, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-23661d7ee429e6b42304a9ad9a97d347780b8f3e24117f703750cf2e02c6e9783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Alternative Splicing</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cell Division - drug effects</topic><topic>Chemotherapy</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Megestrol - adverse effects</topic><topic>Megestrol - therapeutic use</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Receptors, Estrogen - genetics</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Regular</topic><topic>regular-article</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Villa, E</creatorcontrib><creatorcontrib>Ferretti, I</creatorcontrib><creatorcontrib>Grottola, A</creatorcontrib><creatorcontrib>Buttafoco, P</creatorcontrib><creatorcontrib>Buono, M Grazia Del</creatorcontrib><creatorcontrib>Giannini, F</creatorcontrib><creatorcontrib>Manno, M</creatorcontrib><creatorcontrib>Bertani, H</creatorcontrib><creatorcontrib>Dugani, A</creatorcontrib><creatorcontrib>Manenti, F</creatorcontrib><collection>SpringerOpen</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Villa, E</au><au>Ferretti, I</au><au>Grottola, A</au><au>Buttafoco, P</au><au>Buono, M Grazia Del</au><au>Giannini, F</au><au>Manno, M</au><au>Bertani, H</au><au>Dugani, A</au><au>Manenti, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2001-04-06</date><risdate>2001</risdate><volume>84</volume><issue>7</issue><spage>881</spage><epage>885</epage><pages>881-885</pages><issn>0007-0920</issn><issn>1532-1827</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Variant liver oestrogen receptor transcripts in hepatocellular carcinoma are associated with aggressive clinical course and unresponsiveness to tamoxifen. To evaluate the impact on survival and on tumour growth of megestrol (progestin drug acting at post-receptorial level) we enrolled 45 patients with HCC characterized by variant liver oestrogen receptors in a prospective, randomized study with megestrol vs. placebo. Presence of variant oestrogen receptors was determined by RT/PCR. 24 patients were randomized to no treatment and 21 to therapy with megestrol 160 mg day
–1
. Results were analysed by Kaplan-Meier and Cox methods. Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (
P
= 0.0090). Tumour growth at one year was significantly slowed down in megestrol-treated patients (
P
= 0.0212). Bilirubin levels, presence of portal thrombosis, HBV aetiology and treatment were identified at univariate analysis as factors significantly associated with survival; at multivariate analysis, only megestrol therapy (
P
= 0.0003), presence of HBV infection (
P
= 0.0009) and presence of portal vein thrombosis (
P
= 0.0051) were factors independently related with survival. (1) Megestrol slows down the aggressive tumour growth of patients with hepatocellular carcinoma characterized by variant estrogen receptors and (2) is also able to favourably influence the course of disease, more than doubling median survival. © 2001 Cancer Research Campaign</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>11286465</pmid><doi>10.1054/bjoc.2000.1534</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2001-04, Vol.84 (7), p.881-885 |
| issn | 0007-0920 1532-1827 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363845 |
| source | PubMed (Medline) |
| subjects | Alternative Splicing Antineoplastic agents Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Cell Division - drug effects Chemotherapy Drug Resistance Epidemiology Female Humans Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Liver Neoplasms - pathology Male Medical sciences Megestrol - adverse effects Megestrol - therapeutic use Middle Aged Molecular Medicine Oncology Pharmacology. Drug treatments Prospective Studies Receptors, Estrogen - genetics Receptors, Estrogen - metabolism Regular regular-article Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - genetics RNA, Messenger - metabolism Survival Rate |
| title | Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T22%3A40%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hormonal%20therapy%20with%20megestrol%20in%20inoperable%20hepatocellular%20carcinoma%20characterized%20by%20variant%20oestrogen%20receptors&rft.jtitle=British%20journal%20of%20cancer&rft.au=Villa,%20E&rft.date=2001-04-06&rft.volume=84&rft.issue=7&rft.spage=881&rft.epage=885&rft.pages=881-885&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1054/bjoc.2000.1534&rft_dat=%3Cproquest_pubme%3E1008677351%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c484t-23661d7ee429e6b42304a9ad9a97d347780b8f3e24117f703750cf2e02c6e9783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230008684&rft_id=info:pmid/11286465&rfr_iscdi=true |